MMP inhibitors in cardiac diseases: An update

György Dormán, Katalin Kocsis-Szommer, Cesare Spadoni, Péter Ferdinandy

Research output: Contribution to journalArticle

42 Citations (Scopus)


Close to 60 matrix metalloproteinase (MMP) inhibitors have been pursued as clinical candidates since the first drug discovery program targeting this enzyme family began in the late seventies. Targeted indications included cancer, arthritis, cardiovascular diseases, and many others. However, the clinical development of most of the MMP inhibitors have been discontinued due to safety reasons and so far only Periostat (doxycycline hyclate, a nonspecific MMP inhibitor) has been approved for periodontal disease. Because of the high therapeutic potential, the devriopment of MMP inhibitors continues as shown by several recent patents and scientific publications. Development of selective MMP inhibitors lacking serious side-effects such as musculoskeletal syndrome is of high importance. Innovative approaches for the design of selective MMP inhibitors include the integration of classical medicinal chemistry structure-based properties and design features into the emerging chemogenomics concept of target-family based drug discovery. This approach, which includes privileged structures, molecular frameworks, bioisosteric and bioanalogous/isofunctional modifications (the "matrixinome" approach), may lead to highly selective MMP inhibitors in the future.

Original languageEnglish
Pages (from-to)186-194
Number of pages9
JournalRecent Patents on Cardiovascular Drug Discovery
Issue number3
Publication statusPublished - Nov 1 2007



  • Efficacy
  • Heart failure
  • Infarction
  • Inhibitors
  • MMP
  • Matrix metalloproteinase
  • Remodelling
  • Safety
  • Selectivity

ASJC Scopus subject areas

  • Drug Discovery
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this